Active Ingredient History
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cachexia (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Hip Fractures (Phase 2)
Muscle, Skeletal (Phase 2)
Myositis (Phase 2/Phase 3)
Myositis, Inclusion Body (Phase 3)
Obesity (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Respiration, Artificial (Phase 2)
Sarcopenia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue